论文部分内容阅读
目的考察舒肝解郁胶囊对实验性缺血脑卒中的防治作用。方法采用双侧结扎小鼠颈总动脉及迷走神经致急性全脑缺血动物模型和线栓法中动脉阻塞致局灶性缺血脑卒中(MCAO)大鼠模型,通过不同剂量舒肝解郁胶囊干预后,测定全脑缺血小鼠的存活时间、MCAO大鼠血清中5-羟色胺(5-HT)水平、神经功能评分及缺血体积比,评价舒肝解郁胶囊对缺血性脑卒中及运动功能的改善作用。结果舒肝解郁胶囊高、低剂量均可显著延长小鼠脑缺血后的存活时间(P<0.05)。在MCAO模型中,舒肝解郁胶囊中、低剂量均可显著提高血清中5-HT水平(P<0.01),改善模型大鼠的神经运动功能及脑缺血体积比(P<0.05,P<0.01),其作用强度与达纳康相当。结论舒肝解郁胶囊对实验性缺血脑卒中具有良好的防治作用。
Objective To investigate the prevention and treatment of Shugan Jieyu capsule on experimental ischemic stroke. Methods The model of focal cerebral ischemia (MCAO) induced by bilateral occlusion of the common carotid artery and vagus nerve in rats with acute global cerebral ischemia and the model of middle cerebral artery occlusion (MCAO) were established by different doses of Shugan Jieyu Capsule After intervention, the survival time of global cerebral ischemia mice, 5-hydroxytryptamine (5-HT) level, neurological function score and ischemia volume ratio in MCAO rats were measured to evaluate the effect of Shugan Jieyu capsule on ischemic stroke And motor function to improve the role. Results Shugan Jieyu Capsule high and low doses can significantly prolong the survival time of mice after cerebral ischemia (P <0.05). In the MCAO model, low and middle doses of Shugan Jieyu capsule could significantly increase the level of 5-HT in serum (P <0.01) and improve the motor function and volume of cerebral ischemia in model rats (P <0.05, P <0.01), its intensity of action and darnacom equivalent. Conclusion Shugan Jieyu capsule has a good preventive and therapeutic effect on experimental ischemic stroke.